ArticleInternational urology and nephrology2026
Clinical insights on "Adherence to post-therapeutic multidisciplinary tumor board recommendation and its influence on oncological outcomes in high-risk prostate cancer patients following radical prostatectomy".
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We comment on the recent study by Fröhlich et al., which evaluated the influence of adherence to multidisciplinary tumor board (MDT) recommendations on oncological outcomes in high-risk prostate cancer patients following radical prostatectomy. While this study contributes valuable real-world data, we highlight several limitations. Notably, psychosocial factors influencing adherence, such as fear of toxicity and socioeconomic concerns, were not addressed. Additionally, selection bias may have influenced the observed benefits of adjuvant radiotherapy, warranting the use of propensity score methods in future analyses. Finally, the lack of improvement in overall survival despite better biochemical recurrence-free survival raises questions about the clinical relevance of surrogate endpoints. We advocate for broader, patient-centered approaches and methodological rigor in future investigations.
Indexed as
Identifiers
40819328What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.